Turkey: Is Data Exclusivity An Advantage Or An Obstacle For Pharmaceutical Companies In Turkey?
Last Updated: 25 February 2014
Turkish pharmaceutical policy has changed radically and made progress starting from the last decade. In the meantime, some controversial topics such as reimbursement, pricing, authorisation, intellectual property rights, and quality and harmonisation process with the EU were and in fact still are the highly disputed issues. As a consequence of EU harmonisation process, patent, data protection and data exclusivity are one of the foremost areas of the debate. Within the framework of bilateral or multilateral agreements (TRIPs, Customs Union Agreement with the EU) Turkey needed to apply the international terms and conditions of patent and data protection.
More:Is Data Exclusivity An Advantage Or An Obstacle For Pharmaceutical Companies In Turkey? - Food, Drugs, Healthcare, Life Sciences - Turkey
